Scarica l'app Stockscreener
280.44
0.47%
1.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VEEV Giù?
Forum
Previsione
Precedente Chiudi:
$279.32
Aprire:
$280.93
Volume 24 ore:
103.94K
Relative Volume:
0.07
Capitalizzazione di mercato:
$45.83B
Reddito:
$2.86B
Utile/perdita netta:
$780.66M
Rapporto P/E:
59.42
EPS:
4.72
Flusso di cassa netto:
$1.20B
1 W Prestazione:
-1.31%
1M Prestazione:
-1.39%
6M Prestazione:
+30.68%
1 anno Prestazione:
+49.94%
Intervallo 1D:
$278.66
$281.14
Intervallo di 1 settimana:
$270.92
$286.74
Portata 52W:
$177.41
$291.69
Veeva Systems Inc Stock (VEEV) Company Profile
Nome
Veeva Systems Inc
Settore
Industria
Telefono
925-452-6500
Indirizzo
4280 HACIENDA DRIVE, PLEASANTON, CA
Confronta VEEV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
280.44 | 45.86B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
59.11 | 10.13B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
62.01 | 11.55B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
97.42 | 8.92B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.92 | 6.59B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-29 | Reiterato | Needham | Buy |
| 2025-01-23 | Downgrade | Goldman | Buy → Sell |
| 2024-12-20 | Iniziato | Stephens | Overweight |
| 2024-12-04 | Iniziato | Mizuho | Outperform |
| 2024-11-19 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-08 | Iniziato | Exane BNP Paribas | Outperform |
| 2024-08-27 | Reiterato | Citigroup | Buy |
| 2024-07-09 | Iniziato | BTIG Research | Buy |
| 2023-10-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Iniziato | Jefferies | Buy |
| 2023-06-28 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Truist | Buy → Hold |
| 2023-02-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-04 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Iniziato | Cowen | Market Perform |
| 2022-12-02 | Reiterato | Needham | Buy |
| 2022-10-31 | Iniziato | Wells Fargo | Equal Weight |
| 2022-10-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | Goldman | Buy |
| 2022-06-21 | Ripresa | Guggenheim | Buy |
| 2022-03-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2022-01-07 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Ripresa | Stifel | Buy |
| 2021-09-02 | Reiterato | BofA Securities | Buy |
| 2021-09-02 | Reiterato | JMP Securities | Mkt Outperform |
| 2021-09-02 | Reiterato | Needham | Buy |
| 2021-09-02 | Reiterato | UBS | Neutral |
| 2021-07-21 | Iniziato | Cowen | Outperform |
| 2021-03-31 | Aggiornamento | UBS | Sell → Neutral |
| 2021-01-07 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Ripresa | UBS | Sell |
| 2020-08-28 | Reiterato | Needham | Buy |
| 2020-07-23 | Iniziato | FBN Securities | Outperform |
| 2020-07-07 | Iniziato | Stephens | Overweight |
| 2020-06-08 | Iniziato | Citigroup | Buy |
| 2020-05-29 | Reiterato | Needham | Buy |
| 2020-04-13 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-14 | Iniziato | Piper Sandler | Overweight |
| 2020-01-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Reiterato | Canaccord Genuity | Hold |
| 2019-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Reiterato | Needham | Buy |
| 2019-06-07 | Iniziato | Goldman | Neutral |
| 2019-05-30 | Reiterato | BofA/Merrill | Buy |
| 2019-05-30 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Reiterato | Needham | Buy |
| 2019-02-27 | Reiterato | Needham | Buy |
Mostra tutto
Veeva Systems Inc Borsa (VEEV) Ultime notizie
Veeva (VEEV) Expands with Astellas and Sarah Cannon in Global CRM and Oncology Trials - MSN
Veeva Systems and Sarah Cannon Partner to Accelerate Cancer Clinical Trials - MSN
Fresenius Medical Care Reduces Commercial Content Approval by 14 Days - Veeva
Should You Invest in Veeva (VEEV) Based on Bullish Wall Street Views? - Yahoo Finance
Clinical Data Management Systems Market Key Players Analysis - openPR.com
Veeva Systems Trading Volume Drops 38 Percent to 338th Rank Despite Stock Price Rise - AInvest
Why Veeva Systems (VEEV) is a Top Growth Stock for the Long-Term - Yahoo Finance
Veeva Systems (NYSE:VEEV): Strongest Q1 Results from the Vertical Software Group - Yahoo Finance
Veeva Systems (VEEV) Suffers a Larger Drop Than the General Market: Key Insights - MSN
12 Best Cloud Stocks to Buy According to Wall Street Analysts - Insider Monkey
Veeva Systems Surges to 185th in Trading Volume with $451 Million Day Despite Stock Decline - AInvest
Veeva Systems: A Promising Force in the Pharma Cloud Computing Landscape - AInvest
Veeva Systems: A Strong Contender in Cloud Computing for Pharma - MSN
Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock - MSN
Veeva Expands Market Reach Through Targeted Strategic Partnerships - sharewise.com
Veeva Systems (VEEV): Powering MedTech's Clinical Revolution with Data and Compliance - AInvest
Veeva MedTech adoption boosts clinical trials - MarketScreener
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait? - Yahoo Finance
Veeva Systems: Growth Momentum Remains Strong (NYSE:VEEV) - Seeking Alpha
Veeva Systems: Solid Performance, Terrible Price (NYSE:VEEV) - Seeking Alpha
Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Veeva's impact on compliance and efficiency in medtech - Today's Medical Developments
Veeva Systems’ Role in Pioneering Study on Nutrition and Early Development - TipRanks
Veeva Systems Ranks 286th in Trading Volume Despite 3-Day Gain - AInvest
Veeva Systems Trading Volume Drops to $238 Million as Insider Selling Continues - AInvest
Salesforce vs. Veeva: Which Cloud CRM Stock Is the Smarter Buy? - The Globe and Mail
AWS Powers 50+ Veeva Apps: Tech Giants Deepen 10-Year Cloud Partnership for Life Sciences - Stock Titan
If You Invested $1000 in Veeva Systems a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Zacks Market Edge Highlights: Veeva Systems, Howmet Aerospace and Flotek Industries - Zacks Investment Research
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
How to Use the Zacks Rank to Find Top Stocks - TradingView
Veeva Systems: The Strong Quarter May Be A First Of Many To Come (VEEV) - Seeking Alpha
Cook Medical: Empowering Change Champions for a Global RIM Rollout - Veeva
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma - Yahoo Finance
Veeva Systems and PulteGroup have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Bull of the Day: Veeva Systems (VEEV) - Zacks Investment Research
Changing Clinical Operating Models: Lessons from Large Biopharmas - Veeva
Veeva Systems’ SWOT analysis: cloud leader faces competition in life sciences stock - Investing.com Nigeria
Radiometer Scales Clinical Trials with Unified Clinical Platform - Veeva
Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Why Veeva Systems (VEEV) is a Top Momentum Stock for the Long-Term - Yahoo Finance
New Veeva China Campaign Manager Drives Precision Omnichannel Marketing for Life Sciences - Veeva
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility - The Motley Fool
Veeva Systems (NYSE:VEEV) Powers Medtech Trials with Expanded Clinical Platform Adoption - Yahoo Finance
DOCS Boosts Client Retention via Workflow Integration and AI Tools - TradingView
Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech - MarketScreener
Medtech Industry Establishes Foundation for Clinical Trials with - GuruFocus
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech – Company Announcement - Financial Times
Major Medtech Shift: 50+ Companies Achieve 80% Efficiency Gains with Veeva Clinical Platform - Stock Titan
Should You Expect a Large Market Opportunity for Veeva Systems (VEEV)? - MSN
Veeva Systems Inc Azioni (VEEV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):